335 related articles for article (PubMed ID: 10534317)
41. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers.
Koyama E; Chiba K; Tani M; Ishizaki T
J Pharmacol Exp Ther; 1996 Jul; 278(1):21-30. PubMed ID: 8764331
[TBL] [Abstract][Full Text] [Related]
42. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
43. Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate.
Kobayashi K; Mimura N; Fujii H; Minami H; Sasaki Y; Shimada N; Chiba K
Clin Cancer Res; 2000 Aug; 6(8):3297-303. PubMed ID: 10955816
[TBL] [Abstract][Full Text] [Related]
44. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.
Yoshimoto K; Echizen H; Chiba K; Tani M; Ishizaki T
Br J Clin Pharmacol; 1995 Apr; 39(4):421-31. PubMed ID: 7640150
[TBL] [Abstract][Full Text] [Related]
45. Role of human CYP2B6 in S-mephobarbital N-demethylation.
Kobayashi K; Abe S; Nakajima M; Shimada N; Tani M; Chiba K; Yamamoto T
Drug Metab Dispos; 1999 Dec; 27(12):1429-33. PubMed ID: 10570024
[TBL] [Abstract][Full Text] [Related]
46. Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
Ha HR; Chen J; Freiburghaus AU; Follath F
Br J Clin Pharmacol; 1995 Mar; 39(3):321-6. PubMed ID: 7619675
[TBL] [Abstract][Full Text] [Related]
47. Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6.
Bhateria M; Ramakrishna R; Puttrevu SK; Saxena AK; Bhatta RS
Chem Biol Interact; 2016 Aug; 256():257-65. PubMed ID: 27387538
[TBL] [Abstract][Full Text] [Related]
48. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
Ufer M; Svensson JO; Krausz KW; Gelboin HV; Rane A; Tybring G
Eur J Clin Pharmacol; 2004 May; 60(3):173-82. PubMed ID: 15054565
[TBL] [Abstract][Full Text] [Related]
49. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
50. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.
Chang TK; Weber GF; Crespi CL; Waxman DJ
Cancer Res; 1993 Dec; 53(23):5629-37. PubMed ID: 8242617
[TBL] [Abstract][Full Text] [Related]
51. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.
Haaz MC; Rivory L; Riché C; Vernillet L; Robert J
Cancer Res; 1998 Feb; 58(3):468-72. PubMed ID: 9458091
[TBL] [Abstract][Full Text] [Related]
52. Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine.
Kishimoto W; Hiroi T; Sakai K; Funae Y; Igarashi T
Res Commun Mol Pathol Pharmacol; 1997 Dec; 98(3):273-92. PubMed ID: 9485522
[TBL] [Abstract][Full Text] [Related]
53. Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
McCune JS; Risler LJ; Phillips BR; Thummel KE; Blough D; Shen DD
Drug Metab Dispos; 2005 Jul; 33(7):1074-81. PubMed ID: 15821045
[TBL] [Abstract][Full Text] [Related]
54. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC
Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283
[TBL] [Abstract][Full Text] [Related]
55. Regioselectivity of CYP2B6: homology modeling, molecular dynamics simulation, docking.
Bathelt C; Schmid RD; Pleiss J
J Mol Model; 2002 Nov; 8(11):327-35. PubMed ID: 12483228
[TBL] [Abstract][Full Text] [Related]
56. Enantioselective N-demethylation and hydroxylation of sibutramine in human liver microsomes and recombinant cytochrome p-450 isoforms.
Shinde DD; Kim MJ; Jeong ES; Kim YW; Lee JW; Shin JG; Kim DH
J Toxicol Environ Health A; 2014; 77(22-24):1419-30. PubMed ID: 25343291
[TBL] [Abstract][Full Text] [Related]
57. Examination of purported probes of human CYP2B6.
Ekins S; VandenBranden M; Ring BJ; Wrighton SA
Pharmacogenetics; 1997 Jun; 7(3):165-79. PubMed ID: 9241656
[TBL] [Abstract][Full Text] [Related]
58. New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.
Di Marco MP; Wainer IW; Granvil CL; Batist G; Ducharme MP
Pharm Res; 2000 Jun; 17(6):645-52. PubMed ID: 10955835
[TBL] [Abstract][Full Text] [Related]
59. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes.
Hijazi Y; Boulieu R
Drug Metab Dispos; 2002 Jul; 30(7):853-8. PubMed ID: 12065445
[TBL] [Abstract][Full Text] [Related]
60. Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.
Coles R; Kharasch ED
Pharm Res; 2008 Jun; 25(6):1405-11. PubMed ID: 18219560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
